DalsnaFinance

Zepto Life Technology Receives FDA Breakthrough Device Designation for Targeted Liquid Biopsy Test for Invasive Mold Infections

Markets PR Newswire By PR Newswire 03 Jun 2026 14:00 1 min read
Zepto Life Technology Receives FDA Breakthrough Device Designation for Targeted Liquid Biopsy Test for Invasive Mold Infections

ST. PAUL, Minn., June 3, 2026 /PRNewswire/ -- Zepto Life Technology announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the FungiFlex® Mold Panel, a liquid biopsy test designed to aid in the diagnosis of invasive mold infections...

ST. PAUL, Minn., June 3, 2026 /PRNewswire/ -- Zepto Life Technology announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the FungiFlex® Mold Panel, a liquid biopsy test designed to aid in the diagnosis of invasive mold infections...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.